🔴 Lantern Pharma is trading 5.66% down in pre-market — no company-specific explanation confirmed

Lantern Pharma is trading at $0.60, down 5.66% in pre-market, with no confirmed company-specific explanation for the decline.

• No October 19 or October 20 press release appears on the company’s investor-relations page; the latest listed release is October 8.
• The biotech sector is weak, with XBI down 3.65% pre-market, providing context but not a confirmed direct cause.
• The LP-284 patent notice reported October 19 is not a new October 20 catalyst.